Could an 8-Day heart patch prevent your next stroke?
NCT ID NCT05355948
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tested whether wearing a small heart monitor (MEMO Patch PLUS) for 8 to 14 days finds more cases of hidden atrial fibrillation than wearing it for just 1 day. About 1,000 adults aged 75 or older (or with other stroke risk factors) wore the patch. The goal was to see if longer monitoring leads to earlier diagnosis and treatment to prevent strokes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MEMO Patch PLUS (wearable heart monitor)
- What this could lead to
- If longer monitoring detects more hidden atrial fibrillation, it could help prevent strokes by guiding earlier treatment.
- What could go wrong
- This is a completed study, but the benefit depends on whether catching more brief heart rhythm problems actually reduces strokes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
1,000 people
The number who actually took part.
- Started
-
May 2022
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
\[Inclusion criteria\] A participant will be eligible for inclusion in the study if the participant: 1. Has provided documented informed consent for the study. 2. Is adult at least 19 years of age on the day of providing documented informed consent 3. Is the high risk group for stroke, i.e. adult at least 75 years of age or CHA2DS2-VASc score more than 2 4. Is life expectancy more than 6 months 5. Has no Atrial fibrillation or Atrial flutter as a result of 12-lead ECG 6. Has symptoms associated with Atrial fibrillation \*symptoms associated with Atrial fibrillation: palpitation, dizziness, dyspnea, syncope, stroke/transient ischemic accident, systemic embolism etc. \[Exclusion criteria\] The participant must be excluded from the study if the participant: 1. Has had prior history of Atrial fibrillation or Atrial flutter 2. Has inserted Pacemaker or Defibrillator that can diagnose Atrial fibrillation or Atrial flutter 3. Has plan of Carotid endarterectomy or inserting Stent\* within 90 days on the day of providing document informed consent \*Stent insertion: means when stent-related interventions have been performed on the carotid arteyr or coronary arteries.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial fibrillation/flutter in patients with high risk of stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea